Publications of Eckhard Mandelkow
All genres
Journal Article (32)
2023
Journal Article
24 (11), 9260 (2023)
Reversal of Tau-dependent cognitive decay by blocking adenosine A1 receptors: Comparison of transgenic mouse models with different levels of tauopathy. International Journal of Molecular Sciences 2022
Journal Article
59 (6), pp. 3402 - 3413 (2022)
Assessment of the in vivo relationship between cerebral hypometabolism, Tau deposition, TSPO expression, and synaptic density in a tauopathy mouse model: a multi-tracer PET study. Molecular Neurobiology 2019
Journal Article
14, 13 (2019)
Functional networks are impaired by elevated tau-protein but reversible in a regulatable Alzheimer's disease mouse model. Molecular Neurodegeneration
Journal Article
269 (8), pp. 973 - 984 (2019)
Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer’s disease from bioptic olfactory mucosa. European Archives of Psychiatry and Clinical Neuroscience
Journal Article
56 (5), pp. 3751 - 3767 (2019)
Suppressing Tau aggregation and toxicity by an anti-aggregant Tau fragment. Molecular Neurobiology 2018
Journal Article
117, pp. 189 - 202 (2018)
Glutamatergic nervous system degeneration in a C. elegans TauA152T tauopathy model involves pathways of excitotoxicity and Ca2+ dysregulation. Neurobiology of Disease
Journal Article
1779, pp. 99 - 111 (2018)
Purification and characterization of low-n tau oligomers. Methods in Molecular Biology
Journal Article
18 (5), pp. 3271 - 3281 (2018)
Reversible cation-selective attachment and self-assembly of human Tau on supported brain lipid membranes. Nano Letters
Journal Article
37 (7), e98049 (2018)
Tau protein liquid-liquid phase separation can initiate tau aggregation. The EMBO Journal 2017
Journal Article
12, 88 (2017)
Anti-aggregant tau mutant promotes neurogenesis. Molecular Neurodegeneration
Journal Article
57, pp. 47 - 63 (2017)
Time course of Tau toxicity and pharmacologic prevention in a cell model of Tauopathy. Neurobiology of Aging
Journal Article
14 (7), pp. 742 - 752 (2017)
Inhibition of Tau protein aggregation by rhodanine-based compounds solubilized via specific formulation additives to improve bioavailability and cell viability. Current Alzheimer Research
Journal Article
31 (12), pp. 5137 - 5148 (2017)
Caenorhabditis elegans models of tauopathy. The FASEB Journal
Journal Article
5, 91 (2017)
Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathologica Communications
Journal Article
139 (7), pp. 2639 - 2646 (2017)
A two-component adhesive: Tau fibrils arise from a combination of a well-defined motif and conformationally flexible interactions. Journal of the American Chemical Society
Journal Article
292 (29), pp. 12192 - 12207 (2017)
Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture. The Journal of Biological Chemistry 2016
Journal Article
11 (12), e0167432 (2016)
Selection and characterization of tau binding D-enantiomeric peptides with potential for therapy of Alzheimer disease. PLoS One
Journal Article
17 (4), pp. 552 - 569 (2016)
The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity. EMBO Reports
Journal Article
113 (41), pp. 11597 - 11602 (2016)
Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau δK280. Proceedings of the National Academy of Sciences of the United States of America
Journal Article
6, 22685 (2016)
Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo. Scientific Reports